Plasmapheresis and HIV-Associated Thrombotic Microangiopathy: An Institutional Review

Authors

Megan Fisher, MS2, Jefferson Medical College, Thomas Jefferson UniversityFollow
Nancy Edger Hall, RN, MBA, Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, PennsylvaniaFollow
Jennifer Webb, MD, 2Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, PennsylvaniaFollow
Julie Karp, MD, Department of Pathology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PAFollow

Document Type

Poster

Publication Date

6-2014

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a systemic disorder that classically results from a deficiency in the von Willebrand factor-cleaving enzyme, ADAMTS13. The human immunodeficiency virus (HIV) is a secondary cause of TTP. It has been recognized that some patients with HIV-associated TTP do not have a deficiency in ADAMTS13 activity. The role of plasmapheresis (PLEX) in these patients is unclear. This study reviewed 8 cases of HIV-associated TTP at Thomas Jefferson University Hospital. All patients responded to treatment; however, we were unable to make any conclusions regarding the use of PLEX in patients with normal ADAMTS13 activity. HAART initiation is recommended to treat the underlying HIV infection.

Recommended Citation

Fisher, MS2, Megan; Hall, RN, MBA, Nancy Edger; Webb, MD, Jennifer; and Karp, MD, Julie, "Plasmapheresis and HIV-Associated Thrombotic Microangiopathy: An Institutional Review" (2014). Department of Pathology Honors Program Student Research Symposium. Poster 26.
https://jdc.jefferson.edu/phsrs/26